17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resista...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Bagacean, Cristina, Tempescul, Adrian, Ternant, David, Banet, Anne, Douet-Guilbert, Nathalie, Bordron, Anne, Bendaoud, Boutahar, Saad, Hussam, Zdrenghea, Mihnea, Berthou, Christian, Paintaud, Gilles, Renaudineau, Yves
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Short Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6352369/
https://ncbi.nlm.nih.gov/pubmed/30696487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0509-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items